Latest Partnerships News

Bisalloy Steel Group reported steady revenue but strong profit growth and a significant dividend increase for FY25, while outlining ambitious expansion plans for FY26.

Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.

CPT Global Limited reported a 12% revenue increase to $23.1 million for FY2025, driven by growth in the Northern Hemisphere segment, while narrowing its net loss to $706,214. The company is strategically pivoting towards larger markets and investing in technology and talent to fuel future growth.

Rectifier Technologies Ltd reported a significant downturn in FY2025, with revenues falling 30.8% and a shift from profit to loss driven by a global EV market slowdown. The company is responding with cost controls and strategic pivots toward clean energy integration.

Aeeris Ltd reported a 27.7% revenue increase to $4.36 million for FY25, driven by proprietary platform launches and expanded client contracts, while posting a net loss of $632,731. The company is poised for operational scale and cash flow positivity in FY26.

Income Asset Management Group reported a 22% revenue increase and a significant reduction in net loss for FY25, underpinned by strategic cost cuts, debt repayment, and governance enhancements. The Group also launched a new managed account product and announced key board changes.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

OM Holdings reported a significant turnaround to a US$9.6 million loss in H1 2025 despite stable revenue, driven by weaker alloy prices and operational challenges. The company also announced a conditional sale of its 13% stake in the Tshipi Borwa Manganese Mine.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

The Agency Group has delivered a record financial performance in FY2025, with Gross Commission Income surpassing $125 million, driven by strong growth in residential sales and property management. The company’s unique national direct agency model and strategic expansion into emerging markets underpin its positive outlook.

RMA Global Ltd reported a 13% revenue increase to $21.1 million in FY25, driven by growth in the US and New Zealand, alongside steady Australian performance. The company also recorded its first full-year positive operating cash flow, marking a significant financial turnaround.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.